Healthcare Goonewardene discusses Neuroendocrine Tumors (relevant companies EXEL, CATX, BMY, NVS) on an Analyst/Industry conference call to be held on July 24 at 10 am.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Pan Tumor Rollover Study: A Key Update on Long-term Cancer Treatment
- Exelixis price target raised to $48 from $47 at Morgan Stanley
- Exelixis Receives Buy Rating Amid Positive Revenue Guidance and Anticipated Zanza Trial Data
- Exelixis Advances Cancer Treatment with New Phase 1 Study of XL309
- Exelixis price target raised to $56 from $55 at Truist